Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies
Open Access

Exploring Hypoxia in Prostate Cancer With T2-weighted Magnetic Resonance Imaging Radiomics and Pimonidazole Scoring

MICHELLE LEECH, RALPH T.H. LEIJENAAR, TORD HOMPLAND, JOHN GAFFNEY, HEIDI LYNG and LAURE MARIGNOL
Anticancer Research January 2023, 43 (1) 351-357; DOI: https://doi.org/10.21873/anticanres.16170
MICHELLE LEECH
1Applied Radiation Therapy Trinity, Trinity St. James’s Cancer Institute, Discipline of Radiation Therapy, Trinity College, Dublin, Ireland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: leechm@tcd.ie
RALPH T.H. LEIJENAAR
2Independent scholar, Amstenrade, the Netherlands;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TORD HOMPLAND
3Radiumhospitalet, Oslo University Hosptial, Oslo, Norway;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JOHN GAFFNEY
4St. Luke’s Radiation Oncology Network, Dublin, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HEIDI LYNG
3Radiumhospitalet, Oslo University Hosptial, Oslo, Norway;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LAURE MARIGNOL
1Applied Radiation Therapy Trinity, Trinity St. James’s Cancer Institute, Discipline of Radiation Therapy, Trinity College, Dublin, Ireland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Radiomics involves high throughput extraction of mineable precise quantitative imaging features that serve as non-invasive prognostic or predictive biomarkers. High levels of hypoxia are associated with a poorer prognosis in prostate cancer and limit radiation therapy efficacy. Most patients with prostate cancer undergo magnetic resonance imaging (MRI) as a part of their diagnostics, and T2 imaging is the most utilised imaging method. The aim of this study was to determine whether hypoxia in prostate tumors could be identified using a radiomics model extracted from T2-weighted MR images. Materials and Methods: Eighty eight intermediate or high-risk prostate cancer patients were evaluated. Prior to radical prostatectomy, all patients received pimonidazole (PIMO). PIMO hypoxic scores were assigned in whole-mount sections from prostatectomy specimens by an experienced pathologist who was blinded to MRI. The region of interest used for radiomics analysis included the prostatic index tumor. Radiomics extraction yielded 165 features using a special evaluation version of RadiomiX [RadiomiX Research Toolbox version 20180831 (OncoRadiomics SA, Liège, Belgium)] for non-clinical use. Multivariable logistic regression with Elastic Net regularization was utilised using 10 times repeated 10-fold cross-validation to select the best model hyperparameters, optimizing for area under the receiver operating characteristic curve (AUC). Results: The average (out of sample) performance based on the repeated cross validation using the ONESE model yielded an AUC of 0.60±0.2. Shape-based features were the most prominent in the model. Conclusion: The development of a radiomics hypoxia model using T2 weighted MR images, standard in the staging of prostate cancer, is possible.

Key Words:
  • Radiomics
  • MRI
  • prostate cancer
  • hypoxia

Radiomics is a developing field that involves advanced image analysis and high throughput extraction of mineable precise quantitative imaging descriptors or features that serve as non-invasive prognostic or predictive biomarkers (1). The primary function of a predictive biomarker is to accurately determine the outcome of a specified treatment (2). It is based on the hypothesis that tumor characteristics at cellular and genetic levels are captured in the phenotypic patterns seen in medical images (3). These features are often extracted from medical images using advanced mathematical algorithms (4). Currently, imaging features are generally only visually assessed by radiologists or nuclear medicine physicians and described as qualitative biomarkers (3).

High levels of hypoxia are associated with a poorer prognosis in prostate cancer (5). Due to the inefficient oxygenation of tumor vasculature, tumors have been reported to have large regions of hypoxia, relative to the surrounding normal tissue and both acute and chronic hypoxia exist within tumors. Regions of a tumor with a high oxygen concentration are believed to be up to three times more amenable to radiation therapy than hypoxic regions (6). Proteins and gene expression signatures may serve as intrinsic molecular biomarkers in the identification of hypoxia, but to date, none has successfully been implemented in routine clinical practice for the assessment of hypoxia (7). Other methods for identifying hypoxia in tumors include the Eppendorf electrode method and extrinsic markers; such as pimonidazole (PIMO), the latter serving as the method of biological validation in this manuscript. However, the Eppendorf electrode method is an invasive technique and PIMO analysis is not feasible in cases where definitive radiation therapy or chemoradiation therapy are the primary treatments, as no surgical specimen is available.

Medical imaging therefore presents a non-invasive and clinically attractive option for the assessment of hypoxia. Promising imaging techniques such as blood oxygen level dependent and tissue oxygenation level dependent MRI (BOLD-MRI, TOLD-MRI) (8), consumption and supply-based hypoxia MRI (CSH-MRI) (9) or positron emission tomography (PET) using hypoxia-seeking ligands such as fluoro-misonidazole (FMISO), 5 fluoro-azomycin-arabinoside (FAZA) and [18F]HX4 (10, 11) have all been described. However, these advanced imaging techniques do not have the spatial resolution required to fully sample the tumor microenvironment, and both acute and chronic hypoxia are believed to be micro-regional (12).They are also not routine imaging modalities for the staging and management of prostate cancer unlike multiparametric MRI [T2-weighted, diffusion weighted (DW-MRI) and associated apparent diffusion coefficient (ADC) maps] (13). T2-weighted imaging yields relatively high-resolution images of the prostate and surrounding anatomy, allowing for appreciation of structural differences (14), unlike DW-MRI, where spatial resolution is a known limitation (4).

The development of a non-invasive strategy such as radiomics, using routine T2-weighted MR images to identify hypoxic regions within tumors is of much interest in radiation therapy. Most prostate cancer patients undergo MR imaging as a part of their diagnostics, and T2 imaging is the most utilized imaging method. It is highly stable with minor artefacts compared to other MR imaging sequences such as dynamic contrast enhanced MRI and DW-MRI.

Identification of hypoxia on T2-weighted MRI could easily be implemented in the clinic. It would permit dose escalation to hypoxic regions and could lead to improved treatment outcomes, without the need for additional imaging techniques. To date, the data on such an approach have been limited in prostate cancer (15).

The aim of this study was to determine whether hypoxia in prostate tumors could be identified using a radiomics model extracted from T2-weighted MR images (16).

Materials and Methods

The study used irrevocably anonymised data from 88 intermediate or high-risk prostate cancer patients, as per the D’Amico risk classification, recruited as part of the FUNCTPROST study under a data sharing agreement signed between Trinity College Dublin and Oslo University Hospital, Radiumhospitalet, Oslo, Norway. The clinical features of all 88 analysed patients are summarised in Table I.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Summary of patient characteristics.

The methodological steps of the FUNCTPROST study and procedures were previously published (9). Briefly, all consented patients received the hypoxia marker pimonidazole (PIMO) prior to radical prostatectomy at a dose of 500 mg per m2 body surface. MRI scans were acquired adhering to the European Society of Urogenital Radiology (ESUR) 2012 guidelines (17). The imaging parameters of the scan protocol are given in Table II. PIMO hypoxic scores were assigned in whole-mount sections from prostatectomy specimens by an experienced pathologist who was blinded to MRI (Figure 1).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

T2 image scanning parameters.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

PIMO scored prostatectomy specimens and corresponding regions of interest. Left: Pimonidazole (PIMO)-stained whole-mount section from the prostatectomy specimens of two patients, one with a tumor pimonidazole score of 0 (left) and one with a pimonidazole score of 2.5 (right). Tumor outline is indicated. Right: The corresponding region of interest outlined for both patients on T2-Weighted magnetic resonance imaging. The radiomics feature values for two of the model features are given: Shape Max_Diameter and GLSZM-SZN. Note the higher values for the higher PIMO score.

Radiomics region of interest (ROI) definition. The ROI used for radiomics analysis included the prostatic index tumor. The tumor lesion was contoured as part of the FUNCTPROST study on a single axial slice of T2 weighted images by an experienced radiologist. Contouring was aided by the pathological evaluation of hematoxylin and eosin stained whole mount sections.

Radiomics features. Feature extraction was performed using a special evaluation version of RadiomiX [RadiomiX Research Toolbox version 20180831 (OncoRadiomics SA, Liège, Belgium)] for non-clinical use. A total of 165 features were extracted, focused on the index lesion. Prior to feature extraction, all images were normalised to zero mean, unit variance, resampling was performed using 3 mm isotropic voxels, and the bin width utilised was 0.1. The interpolation algorithm utilised was linear. The radiomics pre-processing and feature extraction process is outlined in Figure 2. The features extracted included morphological features, local intensity features, first-order statistics, intensity histogram features, fractal features and the textural feature families of Gray Level Co-occurrence Matrix (GLCM), Gray Level Run Length Matrix (GLRLM), Gray Level Size Zone Matrix (GLSZM), Gray Level Distance Zone Matrix (GLDZM), Neighbouring Gray Tone Difference Matrix (NGTDM), and Neighbourhood Gray Level Deoendence Matrix (NGLDM).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

The steps in the radiomics process. Image acquisition and delineation (Step 1) is followed by image pre-processing to compensate for differences in image acquisition protocols (Step 2). Feature extraction (Step 3) can result in hundreds or thousands of features, which need to be reduced (Step 4) in order to produce a model with a reasonable number of variables that are predictive of a given endpoint (Step 5). ROI: Region of interest.

Statistical analysis. Hypoxia was modelled for statistical analysis using a binary method with PIMO score <3 (not hypoxic) and PIMO score ≥3 (hypoxic). Redundant features with high correlation (ρ>0.9), together with features with near zero variance and linear combinations between features were removed from additional analysis.

Multivariable logistic regression with Elastic Net regularization was utilised using 10 times repeated 10-fold cross-validation in order to determine the optimal model hyperparameters, optimizing for area under the receiver operating characteristic curve (AUC). All features were standardized before modelling. The simplest candidate model (i.e., the model with the fewest non-zero coefficients) within one standard error of the best performing model was selected to reduce the chance of overfitting (ONESE).

Results

The average (out of sample) performance based on the repeated cross validation using the ONESE model yielded an AUC of 0.60±0.2 (Figure 3). The most relevant features in the model were Shape-based. Shape_flatness was the most important feature in the model, followed by Shape_spherDisprop and Shape_MaxDiameter2D1. The relative contribution of each to the model is shown in Figure 4 and examples of feature values from PIMO 0 and PIMO 2.5 scores are given in Figure 1.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Model results yielded an area under the receiver operating curve (AUC) of 0.60.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Relative performance of radiomics features in the hypoxia model. Note the prevalence of Shape-based features. Shape_spherDisprop: Shape_spherical disproportion; GLSZM-SZN: gray-Level size zone matrix-size zone non-uniformity; IH: intensity; Histogram GLSZM_ZE: gray-level size zone matrix- zone entropy; GLRLM_RLV: gray-level run-length matrix-run length variance.

Discussion

Radiomics-based analysis of hypoxia is in its infancy but has the potential to be of high clinical relevance as conventional measurements of tumor hypoxia using functional imaging, molecular biomarkers or direct probes are expensive, time-consuming and, in some instances, invasive (18). Hypoxia is one of the leading causes of failure of radiation therapy and progression of disease (19) and PIMO staining is an established method for the surrogate assessment of the presence and extent of tumor hypoxia (7).

In this analysis, Shape-based features were the most important in the ONESE model and only one textural feature, GLSZM_SZN was reported in the model. There is a paucity of literature on using radiomics to explore hypoxia in prostate cancer. One pilot study on the association between hypoxia gene profiles and multiparametric MRI in prostate cancer identified 16 T2-weighted textural features, which had significant correlations with three hypoxia gene profiles using both sequencing and immunohistochemical techniques (15). GLCM, GLRLM, GLSZM and local binary patterns extracted from multiparametric MRI and three hypoxia-related gene sets were selected for investigation. These included a 15-gene universal hypoxia gene set (GENE15), a 32-gene prostate specific hypoxia gene set (GENE32), and a 44-gene hypoxia gene set (GENE 44). Although limited to six patients, their results, together with the results of our study with a significantly larger patient cohort, hold promise for future larger scale radiomic analyses.

Considering other cancer sites, Beig et al. (20) reported that radiomics textural features were predictive of a hypoxia enrichment score, based on the 21 genes implicated in the hypoxia pathway of glioblastoma multiforme (GBM). Using 180 multiparametric images from GBM patients, three ROIs were defined: oedema, including the non-enhancing tumor; tumor necrosis; and enhancing tumor. On T2-weighted images of the tumor necrosis ROI, the textural feature information measure of correlation 1, which captures co-occurrences and quantifies structural heterogeneity, was identified to be one of the top eight features most associated with hypoxia enrichment score.

By using a methodology similar to that utilised in the current analysis in non-small cell lung cancer (NSCLC), 14 patients who were administered intravenous PIMO within 24 hours of pneumonectomy had their CT images analysed for textural radiomics features (21). Unlike the present study, the ROIs were delineated on the CT images using semi-automation, without reference to the surgical specimens. The textural features that most strongly correlated with PIMO staining were the standard deviation of all pixel values and the mean value of positive pixels.

It is apparent that structural heterogeneity in tumors may identify hypoxia that cannot be determined by traditional analysis of conventional imaging techniques. Radiomics features extracted from T2-weighted MR images have potential in predicting for PIMO score or hypoxia gene profiles. As textural features quantify the occurrence of various patterns in an image and indicate how the signal response at any given voxel relates to those around it (14), they might have potential as a surrogate for the structural heterogeneity displayed by the hypoxic tumor regions.

In the current radiation therapy workflow, even where adaptive radiation therapy (ART) is routine, a methodology to determine regions of hypoxia and thereby the likely sites of treatment failure is largely absent. Knowledge of the specific radiomics features that can predict for hypoxia, which, from the current analysis and the literature, are likely to be shape and texture-based features, gives the potential for radiomics-based adaptation at the treatment unit, specifically the MRI-linear accelerator. A radiomics based targeted radiotherapy (Rad-TRaP) framework for prostate cancer brachytherapy and external beam treatment planning has been previously proposed (22). However, the radiomic features in this Rad-TRaP study predicted only the location of the prostate cancer lesions, not the regions of hypoxia within the lesions. Such a framework however, could be extended in future for the purposes of analysing and adapting therapy based on radiomics features predictive of hypoxia. In nasopharyngeal carcinoma, it has been postulated that utilising pre-treatment MR images can predict patients in need of adaptation during therapy. A T2-weighted model had an AUC of 0.750 when predicting eligibility for ART in nasopharyngeal carcinoma, with six selected radiomics features – sphericity, elongation, kurtosis, and three textural features from the GLDM and NGTDM families (23). However, this focused on adaptation based on geometric or dosimetric features only and not on the presence of hypoxia.

The current analysis was performed on T2-weighted MRIs that had been acquired for diagnostic purposes. Therefore, before such a proposal could be deemed feasible, a similar analysis would have to be conducted on the available sequences on the MR-linear accelerator and confirmed in a validation cohort. Adoption of radiomics analysis into cone beam computed tomography (CBCT) workflow is dependent upon the ability to define the ROI on images of limited quality and subjected to noise, making the MR-linear accelerator a more favourable option. Although it has been determined that some radiomics features are robust to CBCT (24), CBCT radiomics analysis to date has been limited to ascertain prognosis rather than to adapt or intensify treatment, particularly in lung cancer (25).

Limitations. This study has limitations with respect to the radiomics quality score metric (26). No validation was performed in another dataset, data analysed and radiomics package used were not open source, and the study was retrospective in nature.

Conclusion

In this study, we have demonstrated the feasibility of building a radiomics hypoxia model using T2 weighted MR images, standard in the staging of prostate cancer. Our study uniquely trained this model using scores from PIMO-stained whole-mount sections as the biological validation of hypoxia. Revealing the underlying tumor biology from radiomics feature extraction using such standard imaging is an exciting prospect for future study in the era of adaptive radiation therapy and personalised medicine.

Footnotes

  • Authors’ Contributions

    ML generated the research idea, performed the radiomics extraction, statistical analysis and led the manuscript writing. RTL conducted advanced statistical analysis. TH and HL contributed data for the analysis and contributed to writing of the manuscript. JG contributed to writing of the manuscript. LM generated the research idea and contributed to manuscript revision.

  • Conflicts of Interest

    Dr. Ralph T.H. Leijenaar has shares in the company Radiomics (Oncoradiomics SA, Liège, Belgium) and is co-inventor of an issued patent with royalties on radiomics (PCT/NL2014/050728) licensed to the company Radiomics.

  • Received October 28, 2022.
  • Revision received December 8, 2022.
  • Accepted December 12, 2022.
  • Copyright © 2023 The Author(s). Published by the International Institute of Anticancer Research.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

References

  1. ↵
    1. Aerts HJ,
    2. Velazquez ER,
    3. Leijenaar RT,
    4. Parmar C,
    5. Grossmann P,
    6. Carvalho S,
    7. Bussink J,
    8. Monshouwer R,
    9. Haibe-Kains B,
    10. Rietveld D,
    11. Hoebers F,
    12. Rietbergen MM,
    13. Leemans CR,
    14. Dekker A,
    15. Quackenbush J,
    16. Gillies RJ and
    17. Lambin P
    : Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5: 4006, 2014. PMID: 24892406. DOI: 10.1038/ncomms5006
    OpenUrlCrossRefPubMed
  2. ↵
    1. Yaromina A,
    2. Krause M and
    3. Baumann M
    : Individualization of cancer treatment from radiotherapy perspective. Mol Oncol 6(2): 211-221, 2012. PMID: 22381063. DOI: 10.1016/j.molonc.2012.01.007
    OpenUrlCrossRefPubMed
  3. ↵
    1. Yip SS and
    2. Aerts HJ
    : Applications and limitations of radiomics. Phys Med Biol 61(13): R150-R166, 2016. PMID: 27269645. DOI: 10.1088/0031-9155/61/13/R150
    OpenUrlCrossRefPubMed
  4. ↵
    1. Kumar V,
    2. Gu Y,
    3. Basu S,
    4. Berglund A,
    5. Eschrich SA,
    6. Schabath MB,
    7. Forster K,
    8. Aerts HJ,
    9. Dekker A,
    10. Fenstermacher D,
    11. Goldgof DB,
    12. Hall LO,
    13. Lambin P,
    14. Balagurunathan Y,
    15. Gatenby RA and
    16. Gillies RJ
    : Radiomics: the process and the challenges. Magn Reson Imaging 30(9): 1234-1248, 2012. PMID: 22898692. DOI: 10.1016/j.mri.2012.06.010
    OpenUrlCrossRefPubMed
  5. ↵
    1. Milosevic M,
    2. Warde P,
    3. Ménard C,
    4. Chung P,
    5. Toi A,
    6. Ishkanian A,
    7. McLean M,
    8. Pintilie M,
    9. Sykes J,
    10. Gospodarowicz M,
    11. Catton C,
    12. Hill RP and
    13. Bristow R
    : Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin Cancer Res 18(7): 2108-2114, 2012. PMID: 22465832. DOI: 10.1158/1078-0432.CCR-11-2711
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Grimes DR,
    2. Warren DR and
    3. Warren S
    : Hypoxia imaging and radiotherapy: bridging the resolution gap. Br J Radiol 90(1076): 20160939, 2017. PMID: 28540739. DOI: 10.1259/bjr.20160939
    OpenUrlCrossRefPubMed
  7. ↵
    1. Walsh JC,
    2. Lebedev A,
    3. Aten E,
    4. Madsen K,
    5. Marciano L and
    6. Kolb HC
    : The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxid Redox Signal 21(10): 1516-1554, 2014. PMID: 24512032. DOI: 10.1089/ars.2013.5378
    OpenUrlCrossRefPubMed
  8. ↵
    1. Hallac RR,
    2. Zhou H,
    3. Pidikiti R,
    4. Song K,
    5. Stojadinovic S,
    6. Zhao D,
    7. Solberg T,
    8. Peschke P and
    9. Mason RP
    : Correlations of noninvasive BOLD and TOLD MRI with pO2 and relevance to tumor radiation response. Magn Reson Med 71(5): 1863-1873, 2014. PMID: 23813468. DOI: 10.1002/mrm.24846
    OpenUrlCrossRefPubMed
  9. ↵
    1. Hompland T,
    2. Hole KH,
    3. Ragnum HB,
    4. Aarnes EK,
    5. Vlatkovic L,
    6. Lie AK,
    7. Patzke S,
    8. Brennhovd B,
    9. Seierstad T and
    10. Lyng H
    : Combined MR imaging of oxygen consumption and supply reveals tumor hypoxia and aggressiveness in prostate cancer patients. Cancer Res 78(16): 4774-4785, 2018. PMID: 29945958. DOI: 10.1158/0008-5472.CAN-17-3806
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Hoskin PJ
    : Hypoxia dose painting in prostate and cervix cancer. Acta Oncol 54(9): 1259-1262, 2015. PMID: 26148050. DOI: 10.3109/0284186X.2015.1061692
    OpenUrlCrossRefPubMed
  11. ↵
    1. Walsh S,
    2. de Jong EEC,
    3. van Timmeren JE,
    4. Ibrahim A,
    5. Compter I,
    6. Peerlings J,
    7. Sanduleanu S,
    8. Refaee T,
    9. Keek S,
    10. Larue RTHM,
    11. van Wijk Y,
    12. Even AJG,
    13. Jochems A,
    14. Barakat MS,
    15. Leijenaar RTH and
    16. Lambin P
    : Decision support systems in oncology. JCO Clin Cancer Inform 3: 1-9, 2019. PMID: 30730766. DOI: 10.1200/CCI.18.00001
    OpenUrlCrossRefPubMed
  12. ↵
    1. Cao X,
    2. Rao Allu S,
    3. Jiang S,
    4. Jia M,
    5. Gunn JR,
    6. Yao C,
    7. LaRochelle EP,
    8. Shell JR,
    9. Bruza P,
    10. Gladstone DJ,
    11. Jarvis LA,
    12. Tian J,
    13. Vinogradov SA and
    14. Pogue BW
    : Tissue pO(2) distributions in xenograft tumors dynamically imaged by Cherenkov-excited phosphorescence during fractionated radiation therapy. Nat Commun 11(1): 573, 2020. PMID: 31996677. DOI: 10.1038/s41467-020-14415-9
    OpenUrlCrossRefPubMed
  13. ↵
    1. Ginsburg SB,
    2. Algohary A,
    3. Pahwa S,
    4. Gulani V,
    5. Ponsky L,
    6. Aronen HJ,
    7. Boström PJ,
    8. Böhm M,
    9. Haynes AM,
    10. Brenner P,
    11. Delprado W,
    12. Thompson J,
    13. Pulbrock M,
    14. Taimen P,
    15. Villani R,
    16. Stricker P,
    17. Rastinehad AR,
    18. Jambor I and
    19. Madabhushi A
    : Radiomic features for prostate cancer detection on MRI differ between the transition and peripheral zones: Preliminary findings from a multi-institutional study. J Magn Reson Imaging 46(1): 184-193, 2017. PMID: 27990722. DOI: 10.1002/jmri.25562
    OpenUrlCrossRefPubMed
  14. ↵
    1. Cameron A,
    2. Khalvati F,
    3. Haider MA and
    4. Wong A
    : MAPS: A quantitative radiomics approach for prostate cancer detection. IEEE Trans Biomed Eng 63(6): 1145-1156, 2016. PMID: 26441442. DOI: 10.1109/TBME.2015.2485779
    OpenUrlCrossRefPubMed
  15. ↵
    1. Sun Y,
    2. Williams S,
    3. Byrne D,
    4. Keam S,
    5. Reynolds HM,
    6. Mitchell C,
    7. Wraith D,
    8. Murphy D and
    9. Haworth A
    : Association analysis between quantitative MRI features and hypoxia-related genetic profiles in prostate cancer: a pilot study. Br J Radiol 92(1104): 20190373, 2019. PMID: 31356111. DOI: 10.1259/bjr.20190373
    OpenUrlCrossRefPubMed
  16. ↵
    1. Leech M
    : Magnetic resonance imaging radiomics: towards the personalisation of radiation therapy for prostate cancer. Dublin, Ireland, Trinity College Dublin, 2020. Available at: http://www.tara.tcd.ie/bitstream/handle/2262/93383/For%20deposit_07140657%20PhD%20in%20Radiation%20Therapy%20Michelle%20Leech.pdf?sequence=1&isAllowed=y [Last accessed on December 10, 2022]
  17. ↵
    1. Barentsz JO,
    2. Richenberg J,
    3. Clements R,
    4. Choyke P,
    5. Verma S,
    6. Villeirs G,
    7. Rouviere O,
    8. Logager V,
    9. Fütterer JJ and European Society of Urogenital Radiology
    : ESUR prostate MR guidelines 2012. Eur Radiol 22(4): 746-757, 2012. PMID: 22322308. DOI: 10.1007/s00330-011-2377-y
    OpenUrlCrossRefPubMed
  18. ↵
    1. Marcu LG,
    2. Moghaddasi L and
    3. Bezak E
    : Imaging of tumor characteristics and molecular pathways with PET: Developments over the last decade toward personalized cancer therapy. Int J Radiat Oncol Biol Phys 102(4): 1165-1182, 2018. PMID: 29907486. DOI: 10.1016/j.ijrobp.2018.04.055
    OpenUrlCrossRefPubMed
  19. ↵
    1. Fjeldbo CS,
    2. Julin CH,
    3. Lando M,
    4. Forsberg MF,
    5. Aarnes EK,
    6. Alsner J,
    7. Kristensen GB,
    8. Malinen E and
    9. Lyng H
    : Integrative analysis of DCE-MRI and gene expression profiles in construction of a gene classifier for assessment of hypoxia-related risk of chemoradiotherapy failure in cervical cancer. Clin Cancer Res 22(16): 4067-4076, 2016. PMID: 27012812. DOI: 10.1158/1078-0432.CCR-15-2322
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Beig N,
    2. Patel J,
    3. Prasanna P,
    4. Hill V,
    5. Gupta A,
    6. Correa R,
    7. Bera K,
    8. Singh S,
    9. Partovi S,
    10. Varadan V,
    11. Ahluwalia M,
    12. Madabhushi A and
    13. Tiwari P
    : Radiogenomic analysis of hypoxia pathway is predictive of overall survival in Glioblastoma. Sci Rep 8(1): 7, 2018. PMID: 29311558. DOI: 10.1038/s41598-017-18310-0
    OpenUrlCrossRefPubMed
  21. ↵
    1. Ganeshan B,
    2. Goh V,
    3. Mandeville HC,
    4. Ng QS,
    5. Hoskin PJ and
    6. Miles KA
    : Non-small cell lung cancer: histopathologic correlates for texture parameters at CT. Radiology 266(1): 326-336, 2013. PMID: 23169792. DOI: 10.1148/radiol.12112428
    OpenUrlCrossRefPubMed
  22. ↵
    1. Shiradkar R,
    2. Podder TK,
    3. Algohary A,
    4. Viswanath S,
    5. Ellis RJ and
    6. Madabhushi A
    : Radiomics based targeted radiotherapy planning (Rad-TRaP): a computational framework for prostate cancer treatment planning with MRI. Radiat Oncol 11(1): 148, 2016. PMID: 27829431. DOI: 10.1186/s13014-016-0718-3
    OpenUrlCrossRefPubMed
  23. ↵
    1. Yu TT,
    2. Lam SK,
    3. To LH,
    4. Tse KY,
    5. Cheng NY,
    6. Fan YN,
    7. Lo CL,
    8. Or KW,
    9. Chan ML,
    10. Hui KC,
    11. Chan FC,
    12. Hui WM,
    13. Ngai LK,
    14. Lee FK,
    15. Au KH,
    16. Yip CW,
    17. Zhang Y and
    18. Cai J
    : Pretreatment prediction of adaptive radiation therapy eligibility using MRI-based radiomics for advanced nasopharyngeal carcinoma patients. Front Oncol 9: 1050, 2019. PMID: 31681588. DOI: 10.3389/fonc.2019.01050
    OpenUrlCrossRefPubMed
  24. ↵
    1. Fave X,
    2. Mackin D,
    3. Yang J,
    4. Zhang J,
    5. Fried D,
    6. Balter P,
    7. Followill D,
    8. Gomez D,
    9. Jones AK,
    10. Stingo F,
    11. Fontenot J and
    12. Court L
    : Can radiomics features be reproducibly measured from CBCT images for patients with non-small cell lung cancer? Med Phys 42(12): 6784-6797, 2015. PMID: 26632036. DOI: 10.1118/1.4934826
    OpenUrlCrossRefPubMed
  25. ↵
    1. Shi L,
    2. Rong Y,
    3. Daly M,
    4. Dyer B,
    5. Benedict S,
    6. Qiu J and
    7. Yamamoto T
    : Cone-beam computed tomography-based delta-radiomics for early response assessment in radiotherapy for locally advanced lung cancer. Phys Med Biol 65(1): 015009, 2020. PMID: 31307024. DOI: 10.1088/1361-6560/ab3247
    OpenUrlCrossRefPubMed
  26. ↵
    1. Lambin P,
    2. Leijenaar RTH,
    3. Deist TM,
    4. Peerlings J,
    5. de Jong EEC,
    6. van Timmeren J,
    7. Sanduleanu S,
    8. Larue RTHM,
    9. Even AJG,
    10. Jochems A,
    11. van Wijk Y,
    12. Woodruff H,
    13. van Soest J,
    14. Lustberg T,
    15. Roelofs E,
    16. van Elmpt W,
    17. Dekker A,
    18. Mottaghy FM,
    19. Wildberger JE and
    20. Walsh S
    : Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 14(12): 749-762, 2017. PMID: 28975929. DOI: 10.1038/nrclinonc.2017.141
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 43 (1)
Anticancer Research
Vol. 43, Issue 1
January 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Exploring Hypoxia in Prostate Cancer With T2-weighted Magnetic Resonance Imaging Radiomics and Pimonidazole Scoring
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
4 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Exploring Hypoxia in Prostate Cancer With T2-weighted Magnetic Resonance Imaging Radiomics and Pimonidazole Scoring
MICHELLE LEECH, RALPH T.H. LEIJENAAR, TORD HOMPLAND, JOHN GAFFNEY, HEIDI LYNG, LAURE MARIGNOL
Anticancer Research Jan 2023, 43 (1) 351-357; DOI: 10.21873/anticanres.16170

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Exploring Hypoxia in Prostate Cancer With T2-weighted Magnetic Resonance Imaging Radiomics and Pimonidazole Scoring
MICHELLE LEECH, RALPH T.H. LEIJENAAR, TORD HOMPLAND, JOHN GAFFNEY, HEIDI LYNG, LAURE MARIGNOL
Anticancer Research Jan 2023, 43 (1) 351-357; DOI: 10.21873/anticanres.16170
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Correlation of Preclinical In Vivo Imaging Modalities and Immunohistochemistry for Tumor Hypoxia and Vasculature
  • Google Scholar

More in this TOC Section

  • Fucoidan Treatment Leads to Attenuated Growth Factor Signaling and Reduced Proliferation in Neuroblastoma Cells
  • Tetrahydroindazolone-substituted Benzamide Compound W-H4 Induces Apoptosis and Autophagy of Acute Myeloid Leukemia Cells
  • Heterogeneous c-Met Activation in Osteosarcoma Dictates Synergistic Vulnerability to Combined c-Met Inhibition and Methotrexate Therapy
Show more Experimental Studies

Similar Articles

Keywords

  • radiomics
  • MRI
  • Prostate cancer
  • Hypoxia
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire